Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Reckitt Benckiser Healthcare (UK) Ltd
Freepost, RSBU-TEBT-GSTU, Reckitt Benckiser, Kingston Upon Thames, KT2 6LZ, UK
Telephone: +44 (0)500 455 456
WWW: http://www.reckittbenckiser.com
Medical Information Direct Line: +44 (0)500 455 456
Customer Care direct line: +44 (0)500 455 456

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 26/07/2010
SPC Mycil Powder


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Mycil Powder.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Tolnaftate BP 1.0% w/w

Chlorhexidine hydrochloride BP 0.25% w/w.


Go to top of the page
3. PHARMACEUTICAL FORM

Powder.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the adjunctive treatment and prevention of athlete's foot (Tinea Pedis). It may also be helpful in conditions where tenderness and sweating cause skin irritation. It is also effective in other conditions, such as dhobie itch (Tinea Cruris) and prickly heat (Miliaria) and tenderness due to excessive perspiration.


Go to top of the page
4.2 Posology and method of administration

For topical application to the skin.

Wash and thoroughly dry the affected area before applying the powder liberally morning and night. Continue the treatment for at least a week after the infection has cleared up.


Go to top of the page
4.3 Contraindications

None known.


Go to top of the page
4.4 Special warnings and precautions for use

None known.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

No special precautions necessary.


Go to top of the page
4.7 Effects on ability to drive and use machines

Not applicable.


Go to top of the page
4.8 Undesirable effects

None known.


Go to top of the page
4.9 Overdose

Not applicable.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Tolnaftate is a well established drug substance having potent antifungal properties.

Chlorhexidine hydrochloride is a well established drug substance having potent antimicrobial properties.


Go to top of the page
5.2 Pharmacokinetic properties

Not applicable.


Go to top of the page
5.3 Preclinical safety data

There are no preclinical safety data of relevance to the consumer.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Aerosil 200,

Purified talc,

Maize starch.


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

3 years.


Go to top of the page
6.4 Special precautions for storage

None.


Go to top of the page
6.5 Nature and contents of container

Tins with polythene closures or printed white or blue plastic bottles with plastic plug and screw cap containing 55g.


Go to top of the page
6.6 Special precautions for disposal and other handling

None.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Reckitt Benckiser Healthcare (UK) Limited

Dansom Lane

Hull

HU8 7DS

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 00063/0408


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

27.02.1991 / 30.03.2009


Go to top of the page
10. DATE OF REVISION OF THE TEXT

30/03/2009



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/23348/SPC/


Active Ingredients/Generics

 
  chlorhexidine hydrochloride
  tolnaftate